Targeting Pol 1 could rewire cancer cells and suppress tumor growth, Johns Hopkins study finds

Samra Turajlić appointed director of Cancer Research UK Manchester Institute

Samra Turajlić was appointed the director of the Cancer Research UK Manchester Institute.

June 20, 2025

OncoHost study offers insights into resistance mechanisms in immunotherapy-treated lung cancer

A recent OncoHost study provides insight in understanding resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer. Through a comprehensive bioinformatic analysis of pretreatment plasma proteomic profiles from 272 NSCLC patients, researchers identified key biological processes associated with resistance and revealed therapeutic targets that could inform future precision treatment strategies.

June 06, 2025

Vol.51 No.22

Clinical Roundup

Study uncovers source of genetic variation influencing childhood brain tumors

Researchers at Baylor College of Medicine and collaborating institutions investigated for the first time in cancer the association between two sources of genetic variation: germline or inherited structural variation, which refers to large differences in the DNA sequence, and DNA methylation, which is when genes are turned on or off without altering the DNA code.

May 23, 2025

Vol.51 No.20

Clinical Roundup

Genetic mutation in some Ashkenazi Jewish men may be linked to higher prostate cancer risk, study shows

A Johns Hopkins Medicine-led research team has identified a recurrent frameshift mutation, called F722fs, in the MMS22L gene among men of Ashkenazi Jewish ancestry that is associated with a higher risk of prostate cancer and increased sensitivity to a specific anticancer therapy.

May 23, 2025

Vol.51 No.20

Trials & Tribulations

Genetic counseling can improve genetic screening and accelerate clinical trial success

In an effort to target the right patients, genetic screening is becoming more common in clinical trials. But incorporating it can be complex and add a significant burden for both patients and clinical trial sites. Genetic counseling can streamline that process and help drug and gene therapy developers expedite the recruitment of genetically-eligible participants for their trials and use genetic testing results to accelerate the speed and success of clinical trials.

David Liu awarded 2025 Breakthrough Prize in Life Sciences

Howard Hughes Medical Institute Investigator David R. Liu was awarded the 2025 Breakthrough Prize in Life Sciences for developing two gene-editing technologies—known as base editing and prime editing—which enable the correction or replacement of virtually any genetic mutation, including those that cause countless human genetic diseases.

April 11, 2025

Vol.51 No.14

Targeting Pol 1 could rewire cancer cells and suppress tumor growth, Johns Hopkins study finds

YOU MAY BE INTERESTED IN

Samra Turajlić appointed director of Cancer Research UK Manchester Institute

OncoHost study offers insights into resistance mechanisms in immunotherapy-treated lung cancer

Study uncovers source of genetic variation influencing childhood brain tumors

Genetic mutation in some Ashkenazi Jewish men may be linked to higher prostate cancer risk, study shows

Genetic counseling can improve genetic screening and accelerate clinical trial success

David Liu awarded 2025 Breakthrough Prize in Life Sciences

Renew today!

Subscriber content

Never miss an issue!

Login